SRES-232-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S2948; text: CR S2954-2955)
What it does
This resolution designates May 2025 as "National Brain Tumor Awareness Month." It encourages public awareness of brain tumors, expresses Senate support for patients, families, and caregivers, and urges a collaborative approach to brain tumor research. It does not appropriate funds, create programs, or impose any legal obligations.
Who benefits
Brain tumor patients and their families and caregivers, who receive public recognition and symbolic support. Nonprofit brain tumor advocacy organizations, which may gain visibility and public engagement. Researchers in the brain tumor field, who benefit from increased public awareness of the need for funding and collaboration. Pediatric cancer communities, given that brain tumors are the leading cause of cancer death in children under 14.
Who is hurt
No group is materially harmed by this resolution. As a purely symbolic, non-binding measure, it imposes no costs, restrictions, or obligations on any individual, organization, or government entity.
Supporters argue
Supporters argue that brain tumors are among the most underfunded and treatment-resistant cancers — with a 5-year survival rate of only 35.7% for malignant cases and mortality rates largely unchanged over 30 years — making public awareness campaigns especially important. They contend that designating an official awareness month helps unite advocates, draw media attention, and signal congressional commitment to a disease that disproportionately kills children and young adults.
Opponents argue
Opponents might argue that symbolic resolutions consume limited legislative floor time without producing measurable outcomes, and that the Senate's attention would be better directed toward substantive legislation — such as increased NIH appropriations or streamlined FDA approval pathways — that could directly address the treatment gaps and stagnant survival rates the resolution itself acknowledges. They contend that awareness designations, while well-intentioned, have not been shown to translate into improved research funding or patient outcomes.